Skip to main content

Articles

Page 2 of 25

  1. Diagnostic performance of optical coherence tomography (OCT) to detect Alzheimer’s disease (AD) and mild cognitive impairment (MCI) remains limited. We assessed whether compensating the circumpapillary retinal...

    Authors: Jacqueline Chua, Chi Li, Lucius Kang Hua Ho, Damon Wong, Bingyao Tan, Xinwen Yao, Alfred Gan, Florian Schwarzhans, Gerhard Garhöfer, Chelvin C. A. Sng, Saima Hilal, Narayanaswamy Venketasubramanian, Carol Y. Cheung, Georg Fischer, Clemens Vass, Tien Yin Wong…
    Citation: Alzheimer's Research & Therapy 2022 14:41
  2. Temporary disruption of the blood-brain barrier (BBB) using pulsed ultrasound leads to the clearance of both amyloid and tau from the brain, increased neurogenesis, and mitigation of cognitive decline in pre-c...

    Authors: Stéphane Epelbaum, Ninon Burgos, Michael Canney, Dawn Matthews, Marion Houot, Mathieu D. Santin, Carole Desseaux, Guillaume Bouchoux, Sebastian Stroer, Cyril Martin, Marie-Odile Habert, Marcel Levy, Aicha Bah, Karine Martin, Benoît Delatour, Maximilien Riche…
    Citation: Alzheimer's Research & Therapy 2022 14:40
  3. Basic studies suggest that olfactory dysfunction and functional near-infrared spectroscopy (fNIRS) can be used as tools for the diagnosis of mild cognitive impairment (MCI); however, real-world evidence is lac...

    Authors: Jaewon Kim, Dong Keon Yon, Kyu Yeong Choi, Jang Jae Lee, Namwoo Kim, Kun Ho Lee and Jae Gwan Kim
    Citation: Alzheimer's Research & Therapy 2022 14:39
  4. Analysis of functional brain networks in Alzheimer’s disease (AD) has been hampered by a lack of reproducible, yet valid metrics of functional connectivity (FC). This study aimed to assess both the sensitivity...

    Authors: Deborah N. Schoonhoven, Casper T. Briels, Arjan Hillebrand, Philip Scheltens, Cornelis J. Stam and Alida A. Gouw
    Citation: Alzheimer's Research & Therapy 2022 14:38
  5. Thioredoxin-80 (Trx80) is a cleavage product from the redox-active protein Thioredoxin-1 and has been previously described as a pro-inflammatory cytokine secreted by immune cells. Previous studies in our group...

    Authors: Julen Goikolea, Gorka Gerenu, Makrina Daniilidou, Francesca Mangialasche, Patrizia Mecocci, Tiia Ngandu, Juha Rinne, Alina Solomon, Miia Kivipelto, Angel Cedazo-Minguez, Anna Sandebring-Matton and Silvia Maioli
    Citation: Alzheimer's Research & Therapy 2022 14:37
  6. An aging society has increased rates of late onset Alzheimer disease dementia (ADD), the most common form of age-related dementia. This neurodegenerative disease disproportionately affects women.

    Authors: Filippo Cieri, Xiaowei Zhuang, Dietmar Cordes, Nikki Kaplan, Jeffery Cummings and Jessica Caldwell
    Citation: Alzheimer's Research & Therapy 2022 14:36
  7. Plasma amyloid-β (Aβ) may facilitate identification of individuals with brain amyloidosis. Gut microbial dysbiosis in Alzheimer’s disease (AD) is increasingly being recognized. However, knowledge about alterat...

    Authors: Can Sheng, Kun Yang, Beiqi He, Wenying Du, Yanning Cai and Ying Han
    Citation: Alzheimer's Research & Therapy 2022 14:35
  8. Alzheimer’s disease (AD) substantially increases health-related costs. This study investigates direct medical costs and characterizes the caregiver burden across AD stages.

    Authors: Virginie Dauphinot, Michele Potashman, Mihaela Levitchi-Benea, Ray Su, Ivana Rubino and Pierre Krolak-Salmon
    Citation: Alzheimer's Research & Therapy 2022 14:34
  9. Positron emission tomography (PET) with amyloid tracers (amy-PET) allows the quantification of pathological amyloid deposition in the brain tissues, including the white matter (WM). Here, we evaluate amy-PET u...

    Authors: Anna M. Pietroboni, Annalisa Colombi, Tiziana Carandini, Luca Sacchi, Chiara Fenoglio, Giorgio Marotta, Andrea Arighi, Milena A. De Riz, Giorgio G. Fumagalli, Massimo Castellani, Marco Bozzali, Elio Scarpini and Daniela Galimberti
    Citation: Alzheimer's Research & Therapy 2022 14:33
  10. Intracranial internal carotid artery (ICA) calcification is a common incidental finding in non-contrast head CT. We evaluated the predictive value of ICAC (ICAC) for future risk of cognitive decline and compar...

    Authors: Farzaneh Rahmani, Marina Nguyen, Charles D. Chen, Nicole McKay, Aylin Dincer, Nelly Joseph-Mathurin, Gengsheng Chen, Jingxia Liu, Hilary L. P. Orlowski, John C. Morris and Tammie L. S. Benzinger
    Citation: Alzheimer's Research & Therapy 2022 14:32
  11. The NIA-AA research framework proposes a purely biological definition of Alzheimer’s disease (AD). This implies that AD can be diagnosed based on biomarker abnormalities, irrespective of clinical manifestation...

    Authors: Jetske van der Schaar, Leonie N. C. Visser, Femke H. Bouwman, Johannes C. F. Ket, Philip Scheltens, Annelien L. Bredenoord and Wiesje M. van der Flier
    Citation: Alzheimer's Research & Therapy 2022 14:31
  12. While Alzheimer disease (AD) is generally considered as a brain disorder, blood biomarkers may be useful for the diagnosis and prediction of AD brain pathology. The APOE ε4 allele has shown cerebrovascular effect...

    Authors: Rebecca Panitch, Junming Hu, Weiming Xia, David A. Bennett, Thor D. Stein, Lindsay A. Farrer and Gyungah R. Jun
    Citation: Alzheimer's Research & Therapy 2022 14:30
  13. Cerebrospinal fluid (CSF) tau and beta-amyloid levels in chronic traumatic encephalopathy (CTE), a disease which can be clinically indistinguishable from Alzheimer’s disease (AD), are largely unknown. We exami...

    Authors: Katherine W. Turk, Alexandra Geada, Victor E. Alvarez, Weiming Xia, Jonathan D. Cherry, Raymond Nicks, Gaoyuan Meng, Sarah Daley, Yorghos Tripodis, Bertrand R. Huber, Andrew E. Budson, Brigid Dwyer, Neil W. Kowall, Robert C. Cantu, Lee E. Goldstein, Douglas I. Katz…
    Citation: Alzheimer's Research & Therapy 2022 14:28
  14. Cortical mean diffusivity is a novel imaging metric sensitive to early changes in neurodegenerative syndromes. Higher cortical mean diffusivity values reflect microstructural disorganization and have been prop...

    Authors: Ignacio Illán-Gala, Victor Montal, Sergi Borrego-Écija, Maria Luisa Mandelli, Neus Falgàs, Ariane E. Welch, Jordi Pegueroles, Miguel Santos-Santos, Alexandre Bejanin, Daniel Alcolea, Oriol Dols-Icardo, Olivia Belbin, Mª. Belén Sánchez-Saudinós, Nuria Bargalló, Sofía González-Ortiz, Albert Lladó…
    Citation: Alzheimer's Research & Therapy 2022 14:27
  15. Plasma biomarkers for Alzheimer’s disease (AD) have broad potential as screening tools in primary care and disease-modifying trials. Detecting elevated amyloid-β (Aβ) pathology to support trial recruitment or ...

    Authors: Andréa L. Benedet, Wagner S. Brum, Oskar Hansson, Thomas K. Karikari, Eduardo R. Zimmer, Henrik Zetterberg, Kaj Blennow and Nicholas J. Ashton
    Citation: Alzheimer's Research & Therapy 2022 14:26
  16. Cholinergic neurotransmitter system dysfunction contributes to cognitive impairment in Alzheimer’s disease and other syndromes. However, the specific cholinergic mechanisms and brain structures involved, time ...

    Authors: David L. Sultzer, Aaron C. Lim, Hailey L. Gordon, Brandon C. Yarns and Rebecca J. Melrose
    Citation: Alzheimer's Research & Therapy 2022 14:25
  17. Increasing evidence implicates oxidative stress (OS) in Alzheimer disease (AD) and mild cognitive impairment (MCI). Depletion of the brain antioxidant glutathione (GSH) may be important in OS-mediated neurodeg...

    Authors: Jinghan Jenny Chen, Mathura Thiyagarajah, Jianmeng Song, Clara Chen, Nathan Herrmann, Damien Gallagher, Mark J. Rapoport, Sandra E. Black, Joel Ramirez, Ana C. Andreazza, Paul Oh, Susan Marzolini, Simon J. Graham and Krista L. Lanctôt
    Citation: Alzheimer's Research & Therapy 2022 14:23
  18. Genetic variants within the APOE locus may modulate Alzheimer’s disease (AD) risk independently or in conjunction with APOE*2/3/4 genotypes. Identifying such variants and mechanisms would importantly advance our ...

    Authors: Michael E. Belloy, Sarah J. Eger, Yann Le Guen, Vincent Damotte, Shahzad Ahmad, M. Arfan Ikram, Alfredo Ramirez, Anthoula C. Tsolaki, Giacomina Rossi, Iris E. Jansen, Itziar de Rojas, Kayenat Parveen, Kristel Sleegers, Martin Ingelsson, Mikko Hiltunen, Najaf Amin…
    Citation: Alzheimer's Research & Therapy 2022 14:22
  19. To evaluate the diagnostic value of plasma β-amyloid (Aβ) seeding activity measured using a newly developed instrument to distinguish Alzheimer’s disease (AD) from other forms of dementia.

    Authors: Jianping Jia, Tingting Li, Jianwei Yang, Baian Chen, Wei Qin, Cuibai Wei, Yang Song, Qigeng Wang, Yan Li and Longfei Jia
    Citation: Alzheimer's Research & Therapy 2022 14:21
  20. Cerebrospinal fluid (CSF) Aβ1–42 levels and the Aβ1–42/Aβ1–40 ratio are markers of amyloid pathology, but previous studies suggest that their levels might be influenced by additional pathophysiological processes.

    Authors: Constance Delaby, Teresa Estellés, Nuole Zhu, Javier Arranz, Isabel Barroeta, María Carmona-Iragui, Ignacio Illán-Gala, Miguel Ángel Santos-Santos, Miren Altuna, Isabel Sala, M. Belén Sánchez-Saudinós, Laura Videla, Sílvia Valldeneu, Andrea Subirana, Mireia Tondo, Francisco Blanco-Vaca…
    Citation: Alzheimer's Research & Therapy 2022 14:20
  21. Gangliosides are highly enriched in the brain and are critical for its normal development and function. However, in some rare neurometabolic diseases, a deficiency in lysosomal ganglioside hydrolysis is pathog...

    Authors: James C. Dodge, Thomas J. Tamsett, Christopher M. Treleaven, Tatyana V. Taksir, Peter Piepenhagen, S. Pablo Sardi, Seng H. Cheng and Lamya S. Shihabuddin
    Citation: Alzheimer's Research & Therapy 2022 14:19
  22. Expanding technologies of early detection of Alzheimer’s disease allow to identify individuals at risk of dementia in early and asymptomatic disease stages. Neuropsychiatric symptoms, such as anxiety and depre...

    Authors: Ayda Rostamzadeh, Anna Kahlert, Franziska Kalthegener and Frank Jessen
    Citation: Alzheimer's Research & Therapy 2022 14:18

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:44

  23. Until now, Mendelian randomization (MR) studies have investigated the causal association of risk factors with Alzheimer’s disease (AD) using large-scale AD genome-wide association studies (GWAS), GWAS by proxy...

    Authors: Haijie Liu, Yang Hu, Yan Zhang, Haihua Zhang, Shan Gao, Longcai Wang, Tao Wang, Zhifa Han, Bao-liang Sun and Guiyou Liu
    Citation: Alzheimer's Research & Therapy 2022 14:17
  24. The progression rates of Alzheimer’s disease (AD) are variable and dynamic, yet the mechanisms that contribute to heterogeneity in progression rates remain ill-understood. Particularly, the role of synergies i...

    Authors: Muhammad Usman Sadiq, Kichang Kwak and Eran Dayan
    Citation: Alzheimer's Research & Therapy 2022 14:16
  25. Alzheimer’s disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder that mainly affects older adults. One of the pathological hallmarks of AD is abnormally aggregated Tau pr...

    Authors: Isabelle Aillaud, Senthilvelrajan Kaniyappan, Ram Reddy Chandupatla, Lisa Marie Ramirez, Sewar Alkhashrom, Jutta Eichler, Anselm H. C. Horn, Markus Zweckstetter, Eckhard Mandelkow, Heinrich Sticht and Susanne Aileen Funke
    Citation: Alzheimer's Research & Therapy 2022 14:15
  26. Dementia with Lewy bodies (DLB) includes various core clinical features that result in different phenotypes. In addition, Alzheimer’s disease (AD) and cerebrovascular pathologies are common in DLB. All this in...

    Authors: Carla Abdelnour, Daniel Ferreira, Marleen van de Beek, Nira Cedres, Ketil Oppedal, Lena Cavallin, Frédéric Blanc, Olivier Bousiges, Lars-Olof Wahlund, Andrea Pilotto, Alessandro Padovani, Mercè Boada, Javier Pagonabarraga, Jaime Kulisevsky, Dag Aarsland, Afina W. Lemstra…
    Citation: Alzheimer's Research & Therapy 2022 14:14
  27. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Jun Pyo Kim, Bo-Hyun Kim, Paula J. Bice, Sang Won Seo, David A. Bennett, Andrew J. Saykin and Kwangsik Nho
    Citation: Alzheimer's Research & Therapy 2022 14:13

    The original article was published in Alzheimer's Research & Therapy 2021 13:164

  28. Sleep disturbances are common in elderly and occur frequently in dementia. The impact of excessive daytime sleepiness (EDS), insomnia complaints, sleep quality, and hypnotics on the risk of all-cause dementia,...

    Authors: Clémence Cavaillès, Claudine Berr, Catherine Helmer, Audrey Gabelle, Isabelle Jaussent and Yves Dauvilliers
    Citation: Alzheimer's Research & Therapy 2022 14:12
  29. The neurobiological origins of the early and predominant behavioral changes seen in the behavioral variant of Alzheimer’s disease (bvAD) remain unclear. A selective loss of Von Economo neurons (VENs) and phylo...

    Authors: E. H. Singleton, Y. A. L. Pijnenburg, P. Gami-Patel, B. D. C. Boon, F. Bouwman, J. M. Papma, H. Seelaar, P. Scheltens, L. T. Grinberg, S. Spina, A. L. Nana, G. D. Rabinovici, W. W. Seeley, R. Ossenkoppele and A. A. Dijkstra
    Citation: Alzheimer's Research & Therapy 2022 14:11
  30. Clinical endpoints for upcoming therapeutic trials in frontotemporal dementia (FTD) are increasingly urgent. Cognitive composite scores are often used as endpoints but are lacking in genetic FTD. We aimed to c...

    Authors: Jackie M. Poos, Katrina M. Moore, Jennifer Nicholas, Lucy L. Russell, Georgia Peakman, Rhian S. Convery, Lize C. Jiskoot, Emma van der Ende, Esther van den Berg, Janne M. Papma, Harro Seelaar, Yolande A. L. Pijnenburg, Fermin Moreno, Raquel Sanchez-Valle, Barbara Borroni, Robert Laforce…
    Citation: Alzheimer's Research & Therapy 2022 14:10
  31. Lipocalin-2 is a glycoprotein that is involved in various physiological and pathophysiological processes. In the brain, it is expressed in response to vascular and other brain injury, as well as in Alzheimer’s...

    Authors: Peter Hermann, Anna Villar-Piqué, Matthias Schmitz, Christian Schmidt, Daniela Varges, Stefan Goebel, Timothy Bunck, Hanna Lindemann, Carla Bogner, Isabel Santana, Inês Baldeiras, Joachim Riggert, Inga Zerr and Franc Llorens
    Citation: Alzheimer's Research & Therapy 2022 14:9
  32. Adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been linked to a decreased risk of dementia, but reverse causality and residual confounding by lifestyle may partly ...

    Authors: Tosca O. E. de Crom, Sanne S. Mooldijk, M. Kamran Ikram, M. Arfan Ikram and Trudy Voortman
    Citation: Alzheimer's Research & Therapy 2022 14:8
  33. Genome-wide association studies (GWAS) have identified numerous susceptibility loci for Alzheimer’s disease (AD). However, utilizing GWAS and multi-omics data to identify high-confidence AD risk genes (ARGs) a...

    Authors: Jiansong Fang, Pengyue Zhang, Quan Wang, Chien-Wei Chiang, Yadi Zhou, Yuan Hou, Jielin Xu, Rui Chen, Bin Zhang, Stephen J. Lewis, James B. Leverenz, Andrew A. Pieper, Bingshan Li, Lang Li, Jeffrey Cummings and Feixiong Cheng
    Citation: Alzheimer's Research & Therapy 2022 14:7
  34. Neurofilament light chain (NFL) level has been suggested as a blood-based biomarker for neurodegeneration in dementia. However, the association between baseline NFL levels and cognitive stage transition or cor...

    Authors: Eun-Hye Lee, Hyuk Sung Kwon, Seong-Ho Koh, Seong Hye Choi, Jeong-Hwa Jin, Jee Hyang Jeong, Jae-Won Jang, Kyung Won Park, Eun-Joo Kim, Hee Jin Kim, Jin Yong Hong, Soo Jin Yoon, Bora Yoon, Ju-Hee Kang, Jong-Min Lee, Hyun-Hee Park…
    Citation: Alzheimer's Research & Therapy 2022 14:6
  35. Monocyte Chemoattractant Protein-1 (MCP-1), a glial-derived chemokine, mediates neuroinflammation and may regulate memory outcomes among older adults. We aimed to explore the associations of plasma MCP-1 level...

    Authors: Juan Luis Sanchez-Sanchez, Kelly V. Giudici, Sophie Guyonnet, Julien Delrieu, Yan Li, Randall J. Bateman, Angelo Parini, Bruno Vellas and Philipe de Souto Barreto
    Citation: Alzheimer's Research & Therapy 2022 14:5
  36. To help clinicians provide timely treatment and delay disease progression, it is crucial to identify dementia patients during the mild cognitive impairment (MCI) stage and stratify these MCI patients into earl...

    Authors: Ziyu Liu, Travis S. Johnson, Wei Shao, Min Zhang, Jie Zhang and Kun Huang
    Citation: Alzheimer's Research & Therapy 2022 14:4
  37. Considering the growing body of evidence suggesting a potential implication of herpesviruses in the development of dementia, several authors have questioned a protective effect of antiherpetic drugs (AHDs) whi...

    Authors: Morgane Linard, Julien Bezin, Emilie Hucteau, Pierre Joly, Isabelle Garrigue, Jean-François Dartigues, Antoine Pariente and Catherine Helmer
    Citation: Alzheimer's Research & Therapy 2022 14:3
  38. Late-life onset neuropsychiatric symptoms are established risk factors for dementia. The mild behavioral impairment (MBI) diagnostic framework was designed to standardize assessment to determine dementia risk ...

    Authors: Byron Creese and Zahinoor Ismail
    Citation: Alzheimer's Research & Therapy 2022 14:2
  39. Fatty acids play prominent roles in brain function as they participate in structural, metabolic and signaling processes. The homeostasis of fatty acids and related pathways is known to be impaired in cognitive...

    Authors: Raúl González-Domínguez, Pol Castellano-Escuder, Sophie Lefèvre-Arbogast, Dorrain Y. Low, Andrea Du Preez, Silvie R. Ruigrok, Hyunah Lee, Catherine Helmer, Mercè Pallàs, Mireia Urpi-Sarda, Alex Sánchez-Pla, Aniko Korosi, Paul J. Lucassen, Ludwig Aigner, Claudine Manach, Sandrine Thuret…
    Citation: Alzheimer's Research & Therapy 2022 14:1
  40. Alzheimer’s disease (AD) is associated with alterations in cortical perfusion that correlate with cognitive impairment. Recently, neural activity in the gamma band has been identified as a driver of arteriolar...

    Authors: Giulia Sprugnoli, Fanny Munsch, Davide Cappon, Rachel Paciorek, Joanna Macone, Ann Connor, Georges El Fakhri, Ricardo Salvador, Giulio Ruffini, Kevin Donohoe, Mouhsin M. Shafi, Daniel Press, David C. Alsop, Alvaro Pascual Leone and Emiliano Santarnecchi
    Citation: Alzheimer's Research & Therapy 2021 13:203
  41. Kallikrein-8 (KLK8) might be an early blood-biomarker of Alzheimer’s disease (AD). We examined whether blood KLK8 is elevated in persons with amnestic mild cognitive impairment (aMCI) which is a precursor of A...

    Authors: Sara Schramm, Martha Jokisch, Karl-Heinz Jöckel, Arne Herring and Kathy Keyvani
    Citation: Alzheimer's Research & Therapy 2021 13:202
  42. The COVID-19 pandemic disrupted Alzheimer disease randomized clinical trials (RCTs), forcing investigators to make changes in the conduct of such trials while endeavoring to maintain their validity. Changing o...

    Authors: Lon S. Schneider, Yuqi Qiu, Ronald G. Thomas, Carol Evans, Diane M. Jacobs, Shelia Jin, Jeffrey A. Kaye, Andrea Z. LaCroix, Karen Messer, David P. Salmon, Mary Sano, Kimberly Schafer and Howard H. Feldman
    Citation: Alzheimer's Research & Therapy 2021 13:201
  43. There are many pathological changes in the brains of Alzheimer’s disease (AD) patients. For many years, the mainstream view on the pathogenesis of AD believes that β-amyloid (Aβ) usually acts independently in ...

    Authors: Ling-Zhi Ma, Hao Hu, Zuo-Teng Wang, Ya-Nan Ou, Qiang Dong, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2021 13:200
  44. Total tau protein (T-Tau) and neurofilament light chain (NfL) have emerged as candidate plasma biomarkers of neurodegeneration, but studies have not compared how these biomarkers cross-sectionally or longitudi...

    Authors: Jordan D. Marks, Jeremy A. Syrjanen, Jonathan Graff-Radford, Ronald C. Petersen, Mary M. Machulda, Michelle R. Campbell, Alicia Algeciras-Schimnich, Val Lowe, David S. Knopman, Clifford R. Jack Jr, Prashanthi Vemuri and Michelle M. Mielke
    Citation: Alzheimer's Research & Therapy 2021 13:199
  45. Chronic traumatic encephalopathy (CTE), a neurodegenerative tauopathy, cannot currently be diagnosed during life. Atrophy patterns on magnetic resonance imaging could be an effective in vivo biomarker of CTE, ...

    Authors: Michael L. Alosco, Asim Z. Mian, Karen Buch, Chad W. Farris, Madeline Uretsky, Yorghos Tripodis, Zachary Baucom, Brett Martin, Joseph Palmisano, Christian Puzo, Ting Fang Alvin Ang, Prajakta Joshi, Lee E. Goldstein, Rhoda Au, Douglas I. Katz, Brigid Dwyer…
    Citation: Alzheimer's Research & Therapy 2021 13:193
  46. Significant cognitive changes as individuals’ age are not being identified in a timely manner, delaying diagnosis and treatments. Use of brief, multi-domain, self-administered, objective cognitive assessment t...

    Authors: Douglas W. Scharre, Shu ing Chang, Haikady N. Nagaraja, Natalie C. Wheeler and Maria Kataki
    Citation: Alzheimer's Research & Therapy 2021 13:192

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:24

  47. Studies using different assays and technologies showed highly promising diagnostic value of plasma phosphorylated (P-)tau levels for Alzheimer’s disease (AD). We aimed to compare six P-tau Simoa assays, includ...

    Authors: Sherif Bayoumy, Inge M. W. Verberk, Ben den Dulk, Zulaiga Hussainali, Marissa Zwan, Wiesje M. van der Flier, Nicholas J. Ashton, Henrik Zetterberg, Kaj Blennow, Jeroen Vanbrabant, Erik Stoops, Eugeen Vanmechelen, Jeffrey L. Dage and Charlotte E. Teunissen
    Citation: Alzheimer's Research & Therapy 2021 13:198
  48. The effect of antidiabetic medication on cognitive function is unclear. We analyzed the association between five antidiabetic drugs and change in Mini-Mental State Examination (MMSE) scores in patients with di...

    Authors: Juraj Secnik, Hong Xu, Emilia Schwertner, Niklas Hammar, Michael Alvarsson, Bengt Winblad, Maria Eriksdotter, Sara Garcia-Ptacek and Dorota Religa
    Citation: Alzheimer's Research & Therapy 2021 13:197